Literature DB >> 2150667

Cytokine control of peripheral-blood CD23 expression and sCD23 release: differential regulation by IL-2 and IL-4.

A Fischer1, T Pfeil, W König.   

Abstract

CD23 expression on peripheral-blood lymphocytes (PBL) was studied under the influence of cytokines. It is shown that IL-2 induced CD23 expression on human peripheral-blood B cells. Evidence is presented that the IL-2 induced CD23 expression and release of soluble CD23 (sCD23) are not mediated by IL-4. In comparison to IL-4, the IL-2-induced CD23 expression and sCD23 release revealed kinetic differences and were not inhibited by anti-IL-4. The prestimulation of PBL with Staphylococcus aureus strains Cowan 1 (SAC) led to a pronounced reduction in basal CD23 expression and to a change in the response of cytokines. Subsequent stimulation with IL-4 induced CD23 to the same extent as on unstimulated cells, whereas the IL-2-induced CD23 expression and sCD23 release were greatly reduced. Interferon gamma showed no effects on the IL-4-stimulated CD23 expression of SAC-PBL, whereas the IL-2-induced CD23 expression was suppressed. Furthermore, we demonstrate that the stimulation with IL-2/IL-4 inhibits the effects of the individual cytokine; this inhibition is also seen for immunoglobulin (E, G, M) synthesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150667     DOI: 10.1159/000235161

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  2 in total

1.  Modulation of cell-bound and soluble CD23, spontaneous and ongoing IgE synthesis of human peripheral blood mononuclear cells by soluble IL-4 receptors and the partial antagonistic IL-4 mutant protein IL-4 (Y124D).

Authors:  B König; A Fischer; W König
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

2.  Hyposensitization to allergic reaction in rDer f 2-sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S.

Authors:  M Yasue; T Yokota; M Fukada; T Takai; M Suko; H Okudaira; Y Okumura
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.